Clinical Trial Update: Karenitecin in Treating Patients With Relapsed or Refractory Non-Small Cell Lung Cancer [Phase 2]

View source ↗

Summary

This update reports the completion of a Phase 2 clinical trial of Karenitecin in patients with relapsed or refractory non-small cell lung cancer.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Non-small Cell Lung Cancer

Drugs mentioned

• Karenitecin

Snippet

Sponsor: Alliance for Clinical Trials in Oncology | Conditions: Lung Cancer | Phase 2 | Status: COMPLETED